<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Canavan, Neil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">DeFronzo, Ralph A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Insulin Resistance as a Major Risk Factor for Cardiovascular Disease</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">32-33</style></pages><abstract><style  face="normal" font="default" size="100%">Insulin resistance is emerging as a major contributor to cardiovascular risk, and the lipotoxicity that is associated with obesity is a key factor in the development of insulin resistance. Recent data that suggest that thiazolidinediones may provide some insight into this issue are reviewed in this article.</style></abstract><number><style face="normal" font="default" size="100%">7</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>